In order to bring antiviral medications to market, companies such as NanoViricides first have to demonstrate repeated pre-clinical in vitro and in vivo successes. That is EXACTLY where this company is at present.
To suggest this company has somehow failed as a developmental stage company because they have not yet brought a drug to market, is like saying a law student has failed in his ultimate goal of becoming a lawyer because he's not yet a lawyer, even though he's in the middle of studying for his first attempt at passing the bar.
And how about those law school loans? Are we also to denigrate the law student for funding his own education, while totally ignoring the necessity for the money and the reality of his vast earning potential once he's earned his degree? Focus only on his tens of thousands of dollars of debts he's amassed and make him out therefore to be irresponsible, dishonest, and doomed to failure? Just because he borrowed money to fund his education -- an education with which he'll earn tens of millions of dollars?
This company has had multiple, stunning successes in their pre-clinical trials, and is well on their way to ultimate success. The share price every day is the product of potential revenues relative to perceived risks, strongly colored by randomness, overall market trends, investor psychology, the effects of funding, etc. Obviously, if they already HAD drugs on the market, share price and market cap would be hugely greater than current levels.
The rest of your post is just more nonsense, especially the repeated fear injection of your mythical "reverse split". This company will never execute a reverse split. That exists only in the minds of those who wish to scare investors with made up crap.
Market Data 
Markets 
AI
